| Drug General Information |
| Drug ID |
D02DJG
|
| Former ID |
DIB015123
|
| Drug Name |
LY-2189102
|
| Synonyms |
Anti-IL-1 beta mAb (cardiovascular disease), Lilly; Anti IL-1 beta antibody (non-insulin dependent diabetes, rheumatoid athritis), Lilly
|
| Drug Type |
Antibody
|
| Indication |
Cardiovascular disorder [ICD10:I00-I99]
|
Phase 2 |
[1]
|
|---|
| Company |
Eli lilly
|
| Target and Pathway |
| Target(s) |
Interleukin-1 beta |
Target Info |
|
[2]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
NF-kappa B signaling pathway
|
|
Apoptosis
|
|
Osteoclast differentiation
|
|
Toll-like receptor signaling pathway
|
|
NOD-like receptor signaling pathway
|
|
Cytosolic DNA-sensing pathway
|
|
Hematopoietic cell lineage
|
|
TNF signaling pathway
|
|
Inflammatory mediator regulation of TRP channels
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Type I diabetes mellitus
|
|
Alzheimer's disease
|
|
Prion diseases
|
|
Salmonella infection
|
|
Pertussis
|
|
Legionellosis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
African trypanosomiasis
|
|
Malaria
|
|
Amoebiasis
|
|
Tuberculosis
|
|
Measles
|
|
Influenza A
|
|
Herpes simplex infection
|
|
Inflammatory bowel disease (IBD)
|
|
Rheumatoid arthritis
|
|
Graft-versus-host disease
|
|
NetPath Pathway
|
Leptin Signaling Pathway
|
|
IL5 Signaling Pathway
|
|
IL1 Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
IL3 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
Wnt Signaling Pathway
|
|
TCR Signaling Pathway
|
|
TNFalpha Signaling Pathway
|
|
Pathway Interaction Database
|
IL27-mediated signaling events
|
|
IL12-mediated signaling events
|
|
IL1-mediated signaling events
|
|
IFN-gamma pathway
|
|
IL23-mediated signaling events
|
|
Cellular roles of Anthrax toxin
|
|
Reactome
|
Interleukin-1 signaling
|
|
Interleukin-1 processing
|
|
CLEC7A/inflammasome pathway
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
Monoamine Transport
|
|
SIDS Susceptibility Pathways
|
|
TCR Signaling Pathway
|
|
Type II interferon signaling (IFNG)
|
|
Senescence and Autophagy in Cancer
|
|
Cytokines and Inflammatory Response
|
|
MAPK Signaling Pathway
|
|
Myometrial Relaxation and Contraction Pathways
|
|
Aryl Hydrocarbon Receptor Pathway
|
|
IL1 and megakaryotyces in obesity
|
|
Hematopoietic Stem Cell Differentiation
|
|
Spinal Cord Injury
|
|
Allograft Rejection
|
|
Alzheimers Disease
|
|
Leptin signaling pathway
|
|
IL-1 signaling pathway
|
|
Interleukin-1 signaling
|
|
Folate Metabolism
|
|
Vitamin B12 Metabolism
|
|
Selenium Micronutrient Network
|
|
Serotonin Transporter Activity
|
|
Regulation of toll-like receptor signaling pathway
|
|
NOD pathway
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00942188) A Study of LY2189102 in Patients With Type 2 Diabetes. U.S. National Institutes of Health. |
|---|
| REF 2 | Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care. 2013Aug;36(8):2239-46. |
|---|
